Hepatocellular carcinoma, curative resection, adjuvant, high-risk, recurrence-free survival, immune checkpoint inhibitor
hepatocellular carcinoma, hepatic resection, non-alcoholic fatty liver disease, overall survival
Amygdalin, Semen Persicae, Metabolic dysfunction-associated steatotic liver disease, Liver sinusoidal endothelial cells, Defenestration
Adjuvant, curative resection, hepatocellular carcinoma, PD-1 inhibitor, up-to-7 criterion
Hepatocellular carcinoma, macrovascular invasion, immune checkpoint inhibitors, tyrosine kinase inhibitors